Crossmark

SOX9 is a dose-dependent metastatic fate determinant in melanoma

Crossref DOI link: https://doi.org/10.1186/s13046-018-0998-6

Published Online: 2019-01-14

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yang, Xintao

Liang, Rui

Liu, Chunxi

Liu, Jessica Aijia

Cheung, May Pui Lai

Liu, Xuelai

Man, On Ying

Guan, Xin-Yuan

Lung, Hong Lok

Cheung, Martin https://orcid.org/0000-0002-3471-8534
Funding

Funding for this research was provided by:

Research Grants Council, University Grants Committee (GRF_17110715, GRF_17114817)

Research Grants Council, University Grants Committee (GRF_17123016)

University Research Committee, University of Hong Kong (201409176166)

University Research Committee, University of Hong Kong (201711159209)
License Information

Text and Data Mining valid from 2019-01-14
More Information

Article History

Received: 18 September 2018

Accepted: 6 December 2018

First Online: 14 January 2019

Ethics approval and consent to participate

: The Committee on the Use of Live Animals in Teaching and Research in the University of Hong Kong (CULATR no: 4005–16) approved all the experimental procedure involving animal experimentation.Surgically procured tumor samples from patients with nevus, primary cutaneous and metastatic melanomas were obtained in the Department of Anesthesiology, Zhejiang Cancer Hospital and Department of Pediatric Surgery, the Second Hospital of Hebei Medical University with informed patients’ consent for research purposes.

: Not applicable.

: The authors declare that they have no competing interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.